• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Class 1 HDAC and HDAC6 inhibition inversely regulates CD38 induction in myeloma cells via interferon-α and ATRA.

作者信息

Bat-Erdene Ariunzaya, Nakamura Shingen, Oda Asuka, Iwasa Masami, Teramachi Jumpei, Ashtar Mohannad, Harada Takeshi, Miki Hirokazu, Tenshin Hirofumi, Hiasa Masahiro, Fujii Shiro, Sogabe Kimiko, Oura Masahiro, Udaka Kengo, Kagawa Kumiko, Yoshida Sumiko, Aihara Ken-Ichi, Kurahashi Kiyoe, Endo Itsuro, Abe Masahiro

机构信息

Department of Haematology, Endocrinology and Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School of Medicine, Tokushima, Japan.

Department of Tissue Regeneration, Tokushima University Graduate School of Oral Sciences, Tokushima, Japan.

出版信息

Br J Haematol. 2019 Jun;185(5):969-974. doi: 10.1111/bjh.15673. Epub 2018 Nov 26.

DOI:10.1111/bjh.15673
PMID:30474853
Abstract
摘要

相似文献

1
Class 1 HDAC and HDAC6 inhibition inversely regulates CD38 induction in myeloma cells via interferon-α and ATRA.1类组蛋白去乙酰化酶（HDAC）和HDAC6抑制通过干扰素-α和全反式维甲酸（ATRA）反向调节骨髓瘤细胞中CD38的诱导。
Br J Haematol. 2019 Jun;185(5):969-974. doi: 10.1111/bjh.15673. Epub 2018 Nov 26.
2
Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab.新型 HDAC6 抑制剂上调多发性骨髓瘤细胞 CD38 表达属类效应，并增强达雷妥尤单抗的疗效。
Leukemia. 2021 Jan;35(1):201-214. doi: 10.1038/s41375-020-0840-y. Epub 2020 Apr 29.
3
Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab.帕比司他可诱导CD38上调，并增强达雷妥尤单抗的抗骨髓瘤疗效。
Blood. 2017 Jun 22;129(25):3386-3388. doi: 10.1182/blood-2017-03-770776. Epub 2017 May 5.
4
Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma.新型组蛋白去乙酰化酶6（HDAC6）抑制剂ACY-241与抗程序性死亡配体1（PD-L1）抗体联合使用可增强多发性骨髓瘤的抗肿瘤免疫力和细胞毒性。
Leukemia. 2018 Mar;32(3):843-846. doi: 10.1038/leu.2017.322. Epub 2017 Nov 6.
5
Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity.多功能组蛋白去乙酰化酶 6 降解剂的开发具有强大的抗骨髓瘤活性。
J Med Chem. 2019 Aug 8;62(15):7042-7057. doi: 10.1021/acs.jmedchem.9b00516. Epub 2019 Jul 17.
6
Optimal Management of Histone Deacetylase Inhibitor-Related Adverse Events in Patients With Multiple Myeloma: A Focus on Panobinostat.多发性骨髓瘤患者中组蛋白去乙酰化酶抑制剂相关不良事件的优化管理：以帕比司他为重点
Clin Lymphoma Myeloma Leuk. 2018 Aug;18(8):501-507. doi: 10.1016/j.clml.2018.05.007. Epub 2018 May 24.
7
Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma.利洛司他联合硼替佐米和地塞米松治疗复发/难治性多发性骨髓瘤：首个选择性组蛋白去乙酰化酶 6 抑制剂
Clin Cancer Res. 2017 Jul 1;23(13):3307-3315. doi: 10.1158/1078-0432.CCR-16-2526. Epub 2017 Jan 4.
8
The HDAC6/8/10 inhibitor TH34 induces DNA damage-mediated cell death in human high-grade neuroblastoma cell lines.HDAC6/8/10 抑制剂 TH34 诱导人高级神经母细胞瘤细胞系中 DNA 损伤介导的细胞死亡。
Arch Toxicol. 2018 Aug;92(8):2649-2664. doi: 10.1007/s00204-018-2234-8. Epub 2018 Jun 9.
9
Molecular dynamics of targeting CD38 in multiple myeloma.靶向多发性骨髓瘤 CD38 的分子动力学。
Br J Haematol. 2021 May;193(3):581-591. doi: 10.1111/bjh.17329. Epub 2021 Feb 11.
10
The selective HDAC6 inhibitor Nexturastat A induces apoptosis, overcomes drug resistance and inhibits tumor growth in multiple myeloma.选择性 HDAC6 抑制剂 Nexturastat A 诱导多发性骨髓瘤细胞凋亡、克服耐药并抑制肿瘤生长。
Biosci Rep. 2019 Mar 22;39(3). doi: 10.1042/BSR20181916. Print 2019 Mar 29.

引用本文的文献

1
All-trans retinoic acid in hematologic disorders: not just acute promyelocytic leukemia.全反式维甲酸在血液系统疾病中的应用：不仅仅局限于急性早幼粒细胞白血病。
Front Pharmacol. 2024 Jul 4;15:1404092. doi: 10.3389/fphar.2024.1404092. eCollection 2024.
2
Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: mechanisms, therapeutic implications, and future perspectives.探索组蛋白去乙酰化酶及组蛋白去乙酰化酶抑制剂在多发性骨髓瘤中的作用：作用机制、治疗意义及未来展望
Exp Hematol Oncol. 2024 Apr 23;13(1):45. doi: 10.1186/s40164-024-00507-5.
3
Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma.
多发性骨髓瘤靶向免疫治疗新前沿的有前景抗原
Cancers (Basel). 2021 Dec 6;13(23):6136. doi: 10.3390/cancers13236136.
4
Immune System Alterations in Multiple Myeloma: Molecular Mechanisms and Therapeutic Strategies to Reverse Immunosuppression.多发性骨髓瘤中的免疫系统改变：逆转免疫抑制的分子机制与治疗策略
Cancers (Basel). 2021 Mar 17;13(6):1353. doi: 10.3390/cancers13061353.
5
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab.使用地西他滨/维奈克拉和达雷妥尤单抗治疗与治疗相关的急性髓系白血病及潜在的多发性骨髓瘤。
Ann Hematol. 2021 Jun;100(6):1637-1640. doi: 10.1007/s00277-021-04490-3. Epub 2021 Mar 13.
6
The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications.JAK-STAT 通路在骨髓微环境中调节骨髓瘤细胞上的 CD38：治疗意义。
Blood. 2020 Nov 12;136(20):2334-2345. doi: 10.1182/blood.2019004332.
7
CD38 Expression by Myeloma Cells and Its Role in the Context of Bone Marrow Microenvironment: Modulation by Therapeutic Agents.骨髓瘤细胞的 CD38 表达及其在骨髓微环境中的作用：治疗药物的调节。
Cells. 2019 Dec 13;8(12):1632. doi: 10.3390/cells8121632.